Abstract
This review article considers the possibilities of combined antiviral therapy in the treatment of patients with COVID-19, based on the analysis of the mechanism of action of known antiviral drugs in the framework of the medical hypothesis. The potential effectiveness of the joint use of viral RNA polymerase inhibitors and a fusion inhibitor in this pathology is discussed. The review discusses the main representatives of these groups of drugs - ribavirin, riamilovir, umifenovir, favipiravir. The efficacy and safety profile of these drugs was analyzed, including the experience of their use in clinical trials conducted during the COVID-19 pandemic, as well as earlier work performed during the SARS and MERS epidemics.
Highlights
The use of viral RNA polymerase inhibitors in combination with a fusion inhibitor in the treatment of patients with COVID-19: hypothesis
United Hospital with Outpatient Department Managing Affairs of the President of the Russian Federation, Moscow, 119285, Russia This review article considers the possibilities of combined antiviral therapy in the treatment of patients with COVID-19, based on the analysis of the mechanism of action of known antiviral drugs in the framework of the medical hypothesis
The review discusses the main representatives of these groups of drugs – ribavirin, riamilovir, umifenovir, favipiravir
Summary
The use of viral RNA polymerase inhibitors in combination with a fusion inhibitor in the treatment of patients with COVID-19: hypothesis. Проанализирован профиль эффективности и безопасности данных препаратов, в том числе опыт их применения в клинических исследованиях, проведённых в период пандемии COVID-19, а также во время эпидемий SARS и MERS. Ключевые слова: COVID-19; противовирусные препараты; ингибиторы вирусных РНК-полимераз; ингибитор фузии; рибавирин; риамиловир; фавипиравир; умифеновир.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
